Dr. Vince Clinical Research Joins the Fight Against the Fentanyl Crisis, Announces Screening of First Subject for Cessation Therapeutics’ Overdose Prevention Therapy in a First-In-Human Trial

OVERLAND PARK, Kan.; August 2, 2023 – Dr. Vince Clinical Research (DVCR), a full-service CRO specializing in Phase I-II clinical trials, announced today the first subject was screened for Cessation Therapeutics’ CSX-1004 in a First-In-Human single ascending dose study...

Dr. Vince Clinical Research Now Green Certified

OVERLAND PARK, Kan.; June 27, 2023 (Business Wire) – Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes...